Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"SparingVision","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfenex Announces Enters New Partnership in Latin America, and Provides CRM197 Business Update","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Peptide","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Peptide","graph2":"SparingVision"},{"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Announces Updated Indication for Dysport\u00ae (abobotulinumtoxinA) for the Treatment of Spasticity in Children","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Large molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Ipsen"}]

Ipsen

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Ipsen Announces Updated Indication for Dysport® (abobotulinumtoxinA) for the Treatment of Spasticity in Children

Details:

United States Food and Drug Administration (FDA) has approved the expanded use of Dysport® (abobotulinumtoxinA) in pediatric patients.

Lead Product(s): Botulinum toxin type A

Therapeutic Area: Musculoskeletal Product Name: Dysport

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 09, 2020

ASK
US

Upload
your Pipeline Activity

SparingVision

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Pfenex Announces Enters New Partnership in Latin America, and Provides CRM197 Business Update

Details:

Adalvo recently entered into a commercialization agreement with a multinational pharmaceutical company to commercialize PF708, upon receipt of marketing authorization, in certain countries in Latin America.

Lead Product(s): Teriparatide

Therapeutic Area: Musculoskeletal Product Name: Livogiva

Highest Development Status: Approved Product Type: Peptide

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 26, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY